246 related articles for article (PubMed ID: 35235745)
1. Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.
Xie Z; Hou S; Yang X; Duan Y; Han J; Wang Q; Liao C
J Med Chem; 2022 May; 65(9):6356-6389. PubMed ID: 35235745
[TBL] [Abstract][Full Text] [Related]
2. Molecules inducing specific cyclin-dependent kinase degradation and their possible use in cancer therapy.
Zheng M; Zhang XY; Chen W; Xia F; Yang H; Yuan K; Yang P
Future Med Chem; 2024 Feb; 16(4):369-388. PubMed ID: 38288571
[TBL] [Abstract][Full Text] [Related]
3. From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy.
Shi Z; Tian L; Qiang T; Li J; Xing Y; Ren X; Liu C; Liang C
J Med Chem; 2022 May; 65(9):6390-6418. PubMed ID: 35485642
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Whittaker SR; Mallinger A; Workman P; Clarke PA
Pharmacol Ther; 2017 May; 173():83-105. PubMed ID: 28174091
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
6. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
Di Giovanni C; Novellino E; Chilin A; Lavecchia A; Marzaro G
Expert Opin Investig Drugs; 2016 Oct; 25(10):1215-30. PubMed ID: 27606939
[TBL] [Abstract][Full Text] [Related]
7. Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer.
Goel B; Tripathi N; Bhardwaj N; Jain SK
Curr Top Med Chem; 2020; 20(17):1535-1563. PubMed ID: 32416692
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
Malínková V; Vylíčil J; Kryštof V
Expert Opin Ther Pat; 2015; 25(9):953-70. PubMed ID: 26161698
[TBL] [Abstract][Full Text] [Related]
9. New Insights into CDK Regulators: Novel Opportunities for Cancer Therapy.
Bury M; Le Calvé B; Ferbeyre G; Blank V; Lessard F
Trends Cell Biol; 2021 May; 31(5):331-344. PubMed ID: 33676803
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment.
Susanti NMP; Tjahjono DH
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361615
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics.
Law ME; Corsino PE; Narayan S; Law BK
Mol Pharmacol; 2015 Nov; 88(5):846-52. PubMed ID: 26018905
[TBL] [Abstract][Full Text] [Related]
12. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
[TBL] [Abstract][Full Text] [Related]
13. The evolution of cyclin dependent kinase inhibitors in the treatment of cancer.
Jhaveri K; Burris Rd HA; Yap TA; Hamilton E; Rugo HS; Goldman JW; Dann S; Liu F; Wong GY; Krupka H; Shapiro GI
Expert Rev Anticancer Ther; 2021 Oct; 21(10):1105-1124. PubMed ID: 34176404
[No Abstract] [Full Text] [Related]
14. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
Chohan TA; Qayyum A; Rehman K; Tariq M; Akash MSH
Biomed Pharmacother; 2018 Nov; 107():1326-1341. PubMed ID: 30257348
[TBL] [Abstract][Full Text] [Related]
15. Progress in the evaluation of CDK inhibitors as anti-tumor agents.
McInnes C
Drug Discov Today; 2008 Oct; 13(19-20):875-81. PubMed ID: 18639646
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase inhibitors as anticancer drugs.
Krystof V; Uldrijan S
Curr Drug Targets; 2010 Mar; 11(3):291-302. PubMed ID: 20210754
[TBL] [Abstract][Full Text] [Related]
17. An Overview of CDK Enzyme Inhibitors in Cancer Therapy.
Mounika P; Gurupadayya B; Kumar HY; Namitha B
Curr Cancer Drug Targets; 2023; 23(8):603-619. PubMed ID: 36959160
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Roskoski R
Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
[TBL] [Abstract][Full Text] [Related]
19. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.
Wesierska-Gadek J; Schmid G
Expert Opin Investig Drugs; 2006 Jan; 15(1):23-38. PubMed ID: 16370931
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in CDK inhibitors for cancer therapy.
Heptinstall AB; Adiyasa I; Cano C; Hardcastle IR
Future Med Chem; 2018 Jun; 10(11):1369-1388. PubMed ID: 29846081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
